Research programme: therapeutic peptides and antibodies - Amgen/Dyax
Latest Information Update: 09 Sep 2008
At a glance
- Originator Amgen; Dyax
- Class Antibodies; Peptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 09 Sep 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 14 Jun 2007 This programme is still in active development
- 24 Aug 2004 Preclinical trials in Undefined in USA (unspecified route)